A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical
- 30 Sep 2019 Planned primary completion date changed from 30 Sep 2019 to 21 Nov 2019.
- 07 Aug 2019 Status changed from recruiting to active, no longer recruiting, according to an Biohaven Pharmaceutical Holding Company media release.
- 07 May 2019 According to a Biohaven Pharmaceutical media release, top-line result from this study is expected in 4Q2019.